Signaling pathways in hepatocellular carcinoma

Area of Science:

• Hepatocellular Carcinoma (HCC) research
• Molecular oncology
• Cancer signaling pathways

Background:

• Advanced hepatocellular carcinoma (HCC) patients have dismal survival rates despite new systemic agents.
• Identifying key pathway deregulation drivers is essential for novel therapeutic targets in HCC.
• Commonly altered pathways include growth factor receptors and cell differentiation pathways.

Purpose of the Study:

• To review the current understanding of deregulated signaling pathways in HCC.
• To highlight emerging pathways and their therapeutic potential.
• To discuss the role of pathway activation as predictive biomarkers.

Main Methods:

• Review of literature on molecular alterations in HCC.
• Analysis of frequently altered signaling pathways (e.g., VEGFR, PI3K-AKT-mTOR, Wnt/β-catenin).
• Exploration of emerging pathways (e.g., tumor microenvironment, non-coding RNA).

Main Results:

• HCC exhibits frequent deregulation in growth factor and cell differentiation pathways.
• Mechanisms include somatic mutations, chromosomal aberrations, and epigenetic changes.
• Emerging pathways like tumor microenvironment and microbiota offer new therapeutic avenues.

Conclusions:

• Targeting deregulated pathways is critical for improving HCC treatment outcomes.
• Aberrant pathway activation shows potential as predictive biomarkers for systemic therapies.
• Further research into novel signaling pathways may yield breakthrough HCC treatments.